| Literature DB >> 33082526 |
Julia Brinkmann1, Christina Lissewski1, Valentina Pinna2, Yoann Vial3,4, Francesca Pantaleoni5, Francesca Lepri5, Paola Daniele2, Birute Burnyte6, Goran Cuturilo7,8, Christine Fauth9, Alper Gezdirici10, Dieter Kotzot9, Elif Yılmaz Güleç10, Violeta Iotova11, Denny Schanze1, Francis Ramond12, Markéta Havlovicová13, Gulen Eda Utine14, Pelin Ozlem Simsek-Kiper14, Milena Stoyanova15, Alain Verloes3, Alessandro De Luca2, Marco Tartaglia5, Hélène Cavé3,4, Martin Zenker16.
Abstract
The RASopathies are a group of clinically and genetically heterogeneous developmental disorders caused by dysregulation of the RAS/MAPK signalling pathway. Variants in several components and regulators of this pathway have been identified as the pathogenetic cause. In 2015, missense variants in A2ML1 were reported in three unrelated families with clinical diagnosis of Noonan syndrome (NS) and a zebrafish model was presented showing heart and craniofacial defects similar to those caused by a NS-associated Shp2 variant. However, a causal role of A2ML1 variants in NS has not been confirmed since. Herein, we report on 15 individuals who underwent screening of RASopathy-associated genes and were found to carry rare variants in A2ML1, including variants previously proposed to be causative for NS. In cases where parental DNA was available, the respective A2ML1 variant was found to be inherited from an unaffected parent. Seven index patients carrying an A2ML1 variant presented with an alternate disease-causing genetic aberration. These findings underscore that current evidence is insufficient to support a causal relation between variants in A2ML1 and NS, questioning the inclusion of A2ML1 screening in diagnostic RASopathy testing.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33082526 PMCID: PMC7940614 DOI: 10.1038/s41431-020-00743-3
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246